Long-term follow-up of BHC001 for transfusion-dependent beta-thalassemia
Follows people with beta-thalassemia who received BHC001 infusions, checking long-term safety and benefit.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study of BHC001 for TDT
Key facts
- Where
- Changsha and Nanning, ChinaSee the 2 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who were already treated with BRL-101 for transfusion-dependent β-thalassemia. It follows them over time to check long-term safety and effect.
- Age
- 5 Years to 35 Years
- Sex
- All sexes can join.
- Disease stage
- Transfusion-dependent β-thalassemia.
- Earlier treatment
- Must have been treated with BRL-101 for transfusion-dependent β-thalassemia.
Main reasons for not taking part
- The record lists no exclusion criteria.
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 5 and 35 years old?
Source: NCT06314529, who can take part
Where in China
- Xiangya Hospital of Central South UniversityChangsha, ChinaContact: Bin Fu, PhDTaking people
- The 923rd Hospital of Joint Logistics Support Force of People's Liberation ArmyNanning, ChinaContact: Xinhua Zhang, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Bioray Laboratories
- Trial code
- NCT06314529
- Record updated
- 18 March 2024
- Original description
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.Read full original descriptionShow less
Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia
Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.
Inclusion: Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s); Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Exclusion: There are no exclusion criteria for this study.